Alto Neuroscience (ANRO) Cash from Operations (2023 - 2026)

Alto Neuroscience has reported Cash from Operations for 4 years, with the latest figure at 27091000.0 in Q1 2026.

• Quarterly Cash from Operations fell 63.63% year-over-year to 27091000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 62304000.0 (down 17.56% YoY) and the FY2025 annual result came in at 51769000.0, down 9.16% from the prior year.
• Cash from Operations slipped to 27091000.0 in Q1 2026 per ANRO's latest filing, from 11516000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 6635000.0 in Q2 2023 and troughed at 27091000.0 in Q1 2026.
• A 4-year average of 12287076.92 and a median of 11524000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations plunged 76.25% in 2024, then climbed 15.42% in 2025.
• Over 4 years, Cash from Operations stood at 11524000.0 in 2023, then retreated by 12.99% to 13021000.0 in 2024, then grew by 11.56% to 11516000.0 in 2025, then plunged by 135.25% to 27091000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 27091000.0, 11516000.0, and 9918000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.